TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

October 9, 2017

Primary Completion Date

June 1, 2020

Study Completion Date

June 1, 2020

Conditions
Metastatic Ovarian Cancer
Interventions
DRUG

Cyclophosphamide

Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.

DRUG

Fludarabine

Fludarabine 25 mg/m2 is administered on day -5 to day -1.

BIOLOGICAL

TIL infusion

The maximum number of expanded TILs are infused over 30-45 minutes on day 0.

DRUG

Interleukin-2

Interleukin-2 is administered as a daily low-dose subcutaneous injection of 2 MIU for a total of 14 days.

DRUG

Ipilimumab

One dose of Ipilimumab 3 mg/kg is administered 14 days prior to surgical removal of tumor tissue for TIL expansion.

DRUG

Nivolumab

Nivolumab 3 mg/kg is administered on day -2 before TIL infusion and every 2 weeks for a total of 4 doses.

Trial Locations (1)

2730

Center for Cancer Immune Therapy Dept. of Hematology/oncology, Copenhagen

All Listed Sponsors
lead

Inge Marie Svane

OTHER

NCT03287674 - TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer | Biotech Hunter | Biotech Hunter